E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
Deepak L. Bhatt,Steven P. Marso,A. Michael Lincoff,Katherine E. Wolski,Stephen G. Ellis,Eric J. Topol +5 more
TL;DR: Abciximab therapy should be strongly considered in diabetic patients undergoing PCI to improve their survival and is noteworthy in those diabetic patients who are also hypertensive and obese and in diabetics undergoing multivessel intervention.
Journal ArticleDOI
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
Victor L. Serebruany,Steven R. Steinhubl,Peter B. Berger,Alex I. Malinin,Jeffrey S. Baggish,Deepak L. Bhatt,Eric J. Topol +6 more
TL;DR: Findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg, despite substantial differences in the reporting patterns of bleeding complications.
Journal ArticleDOI
Troponin T Levels in Patients with Acute Coronary Syndromes, with or without Renal Dysfunction
Ronnier J. Aviles,Arman T. Askari,Bertil Lindahl,Lars Wallentin,Gang Jia,E. Magnus Ohman,Kenneth W. Mahaffey,L. Kristin Newby,Robert M. Califf,Maarten L. Simoons,Eric J. Topol,Peter B. Berger,Michael S. Lauer +12 more
TL;DR: Cardiac troponin T levels predict short-term prognosis in patients with acute coronary syndromes regardless of their level of creatinine clearance, and was independently predictive of risk across the entire spectrum of renal function.
Journal ArticleDOI
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial.
Frederick Feit,Michele D. Voeltz,Michael J. Attubato,A. Michael Lincoff,Derek P. Chew,John A. Bittl,Eric J. Topol,Steven V. Manoukian +7 more
TL;DR: In this paper, the impact of major hemorrhage and its impact on mortality in patients undergoing elective or urgent PCI randomly assigned to heparin plus planned glycoprotein IIb/IIIa inhibitor versus bivalirudin plus provisional GPIs in the REPLACE-2 Trial were determined.
Journal ArticleDOI
Stroke After Thrombolysis Mortality and Functional Outcomes in the GUSTO-I Trial
Joel M. Gore,Christopher B. Granger,Maarten L. Simoons,Michael A. Sloan,W. Douglas Weaver,Harvey D. White,Gabriel I. Barbash,Frans Van de Werf,Philip E. Aylward,Eric J. Topol,Robert M. Califf +10 more
TL;DR: In this paper, the authors analyzed the incidence, timing, and outcomes of stroke in an international trial and found that 1.4% of the patients had a stroke (93% anatomic documentation) and the risk ranged from 1.19% with streptokinase/subcutaneous heparin therapy to 1.64% with combination thrombolytic therapy.